News & Media

Press release 2016/12/29

Medivir completes previously announced oncology programs acquisition

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the acquisitions of the two clinical stage oncology programs from...

Read more

Press release 2016/12/15

Medivir completes the divestment of BioPhausia – a transfer of approx. SEK 870m to the shareholders through a share redemption offer will be proposed

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) announces today that the divestment of BioPhausia AB to Karo Pharma AB has...

Read more

Press release 2016/12/14

Medivir’s fusion inhibitor for the treatment of Respiratory Syncytial Virus infection, MIV-323, enters non-clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-323 has been selected as a candidate drug (CD) from...

Read more

Press release 2016/12/08

MIV-711 Osteoarthritis Trial: Successful third independent review of safety data and trial continues without any modifications

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the independent Data Monitoring Committee (DMC) has had its third...

Read more

Press release 2016/11/28

Medivir announces that Janssen has initiated an open-label phase IIb study of the 3DAA combination of simeprevir, odalasvir and AL-335 (JNJ-4178)

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that a phase IIb open-label study of the combination of simeprevir,...

Read more

Press release 2016/11/10

MEDIVIR AB – INTERIM REPORT, JANUARY – SEPTEMBER 2016

July – September 2016 Net turnover totalled SEK 67.8 million (111.5 m), of which SEK 12.4 million (69.0 m) comprised royalties...

Read more

Press release 2016/11/03

Invitation to conference call and webcast today 3 November, at 14.30 CET

Medivir will be conducting an analyst and investor conference call/webcast today 3 November, at 14.30 CET. Niklas Prager CEO, Ola Burmark...

Read more

Press release 2016/11/02

Medivir strengthens its clinical pipeline by entering into agreement to acquire a portfolio of clinical stage oncology programs

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that it has entered into an agreement to acquire two clinical...

Read more

Press release 2016/11/01

Medivir’s nucleotide polymerase inhibitor for the treatment of liver cancer, MIV-818, enters non-clinical development

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that MIV-818 has been selected as a candidate drug (CD) from...

Read more

Press release 2016/11/01

Medivir divests its pharmaceutical company BioPhausia (Nordic Brands) to Karo Pharma

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that the company has entered into an agreement with Karo Pharma...

Read more

Press release 2016/10/27

MIV-711 osteoarthritis program: Enrollment in the phase IIa study is complete and independent safety review committee again recommends Go Ahead

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces that its first phase IIa trial of MIV-711 for the treatment...

Read more

Press release 2016/10/10

Medivir focuses exclusively on oncology and reorganizes to significantly reduce the cost structure

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announces a reorganization of the company and a significant cost reduction in...

Read more